These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18090059)

  • 21. Next HIV guidelines likely to include salvage therapy.
    AIDS Alert; 1999 Jul; 14(7):76-8. PubMed ID: 11366417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypersensitivity reactions due to abacavir.
    Newsline People AIDS Coalit N Y; 1998 Feb; ():35-6. PubMed ID: 11367446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abacavir hypersensitivity reaction.
    Hewitt RG
    Clin Infect Dis; 2002 Apr; 34(8):1137-42. PubMed ID: 11915004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypersensitivity reactions reported with abacavir.
    AIDS Patient Care STDS; 1998 May; 12(5):405-6. PubMed ID: 11361980
    [No Abstract]   [Full Text] [Related]  

  • 26. Abacavir warning: certain respiratory symptoms can indicate hypersensitivity reaction.
    AIDS Treat News; 2000 Feb; (No 337):7-8. PubMed ID: 11367210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate.
    Fontaine C; Guiard-Schmid JB; Slama L; Essid A; Lukiana T; Rondeau E; Pialoux G
    AIDS; 2005 Nov; 19(16):1927-8. PubMed ID: 16227807
    [No Abstract]   [Full Text] [Related]  

  • 28. Acute respiratory manifestations of the abacavir hypersensitivity reaction.
    Herring SJ; Krieger AC
    AIDS; 2006 Jan; 20(2):301-2. PubMed ID: 16511430
    [No Abstract]   [Full Text] [Related]  

  • 29. Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.
    Kessler HA; Johnson J; Follansbee S; Sension MG; Mildvan D; Sepulveda GE; Bellos NC; Hetherington SV
    Clin Infect Dis; 2002 Feb; 34(4):535-42. PubMed ID: 11797183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to: Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?
    Brothers C; Cutrell A; Scott T; Hernandez J; Moult A
    Int J Clin Pract; 2006 May; 60(5):611-2; author reply 612. PubMed ID: 16700867
    [No Abstract]   [Full Text] [Related]  

  • 31. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.
    Frissen PH; de Vries J; Weigel HM; Brinkman K
    AIDS; 2001 Jan; 15(2):289. PubMed ID: 11216946
    [No Abstract]   [Full Text] [Related]  

  • 32. Identification of abacavir hypersensitivity reaction in health care claims data.
    Nordstrom BL; Norman HS; Dube TJ; Wilcox MA; Walker AM
    Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):289-96. PubMed ID: 17245797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No rechallenge for abacavir.
    AIDS Patient Care STDS; 2004 Dec; 18(12):737. PubMed ID: 15669129
    [No Abstract]   [Full Text] [Related]  

  • 34. Individualising HIV treatment--pharmacogenetics and immunogenetics.
    Telenti A; Aubert V; Spertini F
    Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578
    [No Abstract]   [Full Text] [Related]  

  • 35. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir.
    Phillips EJ; Sullivan JR; Knowles SR; Shear NH
    AIDS; 2002 Nov; 16(16):2223-5. PubMed ID: 12409746
    [No Abstract]   [Full Text] [Related]  

  • 36. Kawasaki-like syndrome: abacavir hypersensitivity?
    Toerner JG; Cvetkovich T
    Clin Infect Dis; 2002 Jan; 34(1):131-3. PubMed ID: 11731962
    [No Abstract]   [Full Text] [Related]  

  • 37. Severe hypersensitivity reactions following reintroduction of abacavir.
    AIDS Read; 2000 Sep; 10(9):525. PubMed ID: 11019447
    [No Abstract]   [Full Text] [Related]  

  • 38. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
    Berka N; Gill JM; Liacini A; O'Bryan T; Khan FM
    Hum Immunol; 2012 Feb; 73(2):164-7. PubMed ID: 22197535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Abacavir-induced liver toxicity in an HIV-infected patient.
    Di Filippo E; Ripamonti D; Rizzi M
    AIDS; 2014 Feb; 28(4):613. PubMed ID: 24469001
    [No Abstract]   [Full Text] [Related]  

  • 40. Detection of abacavir hypersensitivity by ELISpot method.
    Esser S; Jablonka R; Heinemann FM; Reuter S; Jaeger H; von Krosigk A; Schenk-Westkamp P; Schadendorf D; Horn PA; Lindemann M
    Inflamm Allergy Drug Targets; 2012 Jun; 11(3):227-34. PubMed ID: 22338581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.